Next Article in Journal
A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
Previous Article in Journal
The Importance of Cardiac T2* Magnetic Resonance Imaging for Monitoring Cardiac Siderosis in Thalassemia Major Patients
Article

Whole-Body [18F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687

1
School of Medicine, University of Washington, Seattle, WA 98195, USA
2
School of Mathematical Sciences, University College, T12 XF62 Cork, Ireland
3
AIQ Solutions, Madison, WI 53717, USA
4
Department of Medical Physics, University of Wisconsin, Madison, WI 53705, USA
5
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
6
Department of Biostatistics, Brown University, Providence, RI 02912, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Brian D. Ross
Received: 19 March 2021 / Revised: 12 April 2021 / Accepted: 22 April 2021 / Published: 25 April 2021
ACRIN 6687, a multi-center clinical trial evaluating differential response of bone metastases to dasatinib in men with metastatic castration-resistant prostate cancer (mCRPC), used [18F]-fluoride (NaF) PET imaging. We extend previous ACRIN 6687 dynamic imaging results by examining NaF whole-body (WB) static SUV PET scans acquired after dynamic scanning. Eighteen patients underwent WB NaF imaging prior to and 12 weeks into dasatinib treatment. Regional VOI analysis of the most NaF avid bone metastases and an automated whole-body method using Quantitative Total Bone Imaging software (QTBI; AIQ Solutions, Inc., Madison, WI, USA) were used. We assessed differences in tumor and normal bone, between pre- and on-treatment dasatinib, and evaluated parameters in association with PFS and OS. Significant decrease in average SUVmax and average SUVpeak occurred in response to dasatinib. Univariate and multivariate analysis showed NaF uptake had significant association with PFS. Pharmacodynamic changes with dasatinib in tumor bone can be identified by WB NaF PET in men with mCRPC. WB PET has the benefit of examining the entire body and is less complicated than single FOV dynamic imaging. View Full-Text
Keywords: ACRIN 6687; metastatic castration-resistant prostate cancer (mCRPC); bone metastases; [18F]-Fluoride; PET; dasatinib; progression-free survival (PFS); Quantitative Total Bone Imaging (QTBI) ACRIN 6687; metastatic castration-resistant prostate cancer (mCRPC); bone metastases; [18F]-Fluoride; PET; dasatinib; progression-free survival (PFS); Quantitative Total Bone Imaging (QTBI)
Show Figures

Figure 1

MDPI and ACS Style

Muzi, M.; O’Sullivan, F.; Perk, T.G.; Muzi, J.P.; Mankoff, D.A.; Jeraj, R.; Duan, F.; Yu, E.Y. Whole-Body [18F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687. Tomography 2021, 7, 139-153. https://0-doi-org.brum.beds.ac.uk/10.3390/tomography7020013

AMA Style

Muzi M, O’Sullivan F, Perk TG, Muzi JP, Mankoff DA, Jeraj R, Duan F, Yu EY. Whole-Body [18F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687. Tomography. 2021; 7(2):139-153. https://0-doi-org.brum.beds.ac.uk/10.3390/tomography7020013

Chicago/Turabian Style

Muzi, Mark, Finbarr O’Sullivan, Timothy G. Perk, John P. Muzi, David A. Mankoff, Robert Jeraj, Fenghai Duan, and Evan Y. Yu 2021. "Whole-Body [18F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687" Tomography 7, no. 2: 139-153. https://0-doi-org.brum.beds.ac.uk/10.3390/tomography7020013

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop